Cargando…
Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma
BACKGROUND: Recent efficacy studies of asthma biologics have included highly enriched patient populations. Using a similar approach, we examined factors that predict response to omalizumab to facilitate selection of patients most likely to derive the greatest clinical benefit from therapy. METHODS:...
Autores principales: | Casale, T. B., Chipps, B. E., Rosén, K., Trzaskoma, B., Haselkorn, T., Omachi, T. A., Greenberg, S., Hanania, N. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813202/ https://www.ncbi.nlm.nih.gov/pubmed/28859263 http://dx.doi.org/10.1111/all.13302 |
Ejemplares similares
-
Cost-effectiveness of fractional exhaled nitric oxide (FeNO) measurement in predicting response to omalizumab in asthma
por: Brooks, Elizabeth A, et al.
Publicado: (2019) -
Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies
por: Gimenéz-Arnau, Ana M., et al.
Publicado: (2016) -
Omalizumab in patients with severe uncontrolled asthma: well-defined eligibility criteria to promote asthma control
por: de Carvalho-Pinto, Regina Maria, et al.
Publicado: (2017) -
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019) -
Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)